Article Text

PDF
Systematic review
Staphylococcus aureus bacteraemia management: where do we stand and where are we going?
  1. Pamela A Moise1,
  2. George Sakoulas2
  1. 1Department of Medical Affairs, Cubist Pharmaceuticals, Lexington, Massachusetts, USA;
  2. 2University of California San Diego, La Jolla, California, USA
  1. Correspondence to : Dr Pamela A Moise, Department of Medical Affairs, Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, USA; Pamela.Moise{at}cubist.com

Statistics from Altmetric.com

Commentary on: OpenUrlCrossRefPubMedWeb of Science

Context

Staphylococcus aureus is a common cause of bacteraemia from hospitalised patients in the USA. It is also a very prevalent bacterial pathogen among clinical isolates from outpatients. Despite our technological innovations within and outside of the practice of science and medicine in the past two decades, mortality due to S. aureus bacteremia (SaB) has not changed during this time, remaining at about 20%. The goals of this review were to determine which patients with SaB need transesophageal echocardiography (TEE) and to determine the optimal antibiotic regimen.

Methods

This largely narrative review by Holland and colleagues provides a thorough literature review on the clinical data on which therapeutic and diagnostic standards in …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.